Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To compare the hematological remission, defined as CR (both CR and CRi), as reported by the external independent endpoint adjudication committee, in patients with relapsed/refractory ALL randomized to receive inotuzumab ozogamicin (Arm A) versus patients randomized to receive active comparator (Arm B).
Inclusion criteria
- Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia